Following blood and tumor markers in colorectal cancer during treatment
Studies how colorectal cancer that has spread changes over time during chemotherapy in adults.
Plain-language title generated from the registry record
Registry title: On-treatment Biomarkers in Metastatic Colorectal Cancer for Life
Key facts
- Where
- Lund and Malmö, SwedenSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic colorectal cancer that had already spread when it was found, and who will have treatment meant to remove all of the disease at Skåne University Hospital.
- Age
- 18 to 110 years
- Sex
- All sexes can join
- Disease stage
- Colorectal cancer that had already spread to other organs at diagnosis (synchronous metastatic colorectal cancer)
Main reasons for not taking part
- Informed consent not given
- Age below or above the age limit
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 110 years old?
Source: NCT05755672, who can take part
Where in Sweden
- Department of Oncology, Hematology and Radiophysics, Skane University HospitalLund, SwedenContact: Jakob Eberhard, M.D. PhD.Taking people
- Department of Oncology, Hematology and Radiophysics, Skane University HospitalMalmö, SwedenContact: Christina Siesing, M.D. PhD.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Region Skane
- Trial code
- NCT05755672
- Record updated
- 17 July 2025
- Original description
By virtue of an increased strategic use of cytotoxic and biological agents, and more options for locoregional treatment, the survival of patients with metastatic colorectal cancer (mCRC) has improved considerably in the past decades. The personalized approach to systemic treatment is further aided by the use of complementary molecular biomarkers. However, the evolutionary dynamics of mCRC, a disease harnessed by multiple adaptive genetic alterations towards its final stages, poses a particular challenge to single-sample biomarker analyses and standardized linear treatment protocols. The aim of the On-treatment biomarkers in metastatic ColorectAL cancer for Life (On-CALL) study is to generate further knowledge on the evolutionary progression of mCRC during treatment, and to elucidate the mechanisms underlying the therapeutic failure still seen in a substantial number of patients.Read full original descriptionShow less
On-treatment Biomarkers in Metastatic Colorectal Cancer for Life: The On-CALL Study
By virtue of an increased strategic use of cytotoxic and biological agents, and more options for locoregional treatment, the survival of patients with metastatic colorectal cancer (mCRC) has improved considerably in the past decades. The personalized approach to systemic treatment is further aided by the use of complementary molecular biomarkers. However, the evolutionary dynamics of mCRC, a disease harnessed by multiple adaptive genetic alterations towards its final stages, poses a particular challenge to single-sample biomarker analyses and standardized linear treatment protocols. The aim of the On-treatment biomarkers in metastatic ColorectAL cancer for Life (On-CALL) study is to generate further knowledge on the evolutionary progression of mCRC during treatment, and to elucidate the mechanisms underlying the therapeutic failure still seen in a substantial number of patients.
The On-CALL study is a prospective, single-arm observational study. All patients diagnosed with synchronous mCRC treated with curative intent at Skåne University Hospital will be invited to participate. Clinical and histopathological data will be compiled at study entry. An individual tissue microarray block with samples from resected primary tumours and metastases representing the full extent of the tumour spread will be constructed for each patient. Blood samples will be drawn for biomarker analyses at multiple time points prior to, during and after systemic treatment. DNA sequencing of tumour tissue and circulating tumour DNA (ctDNA) will be performed to define the spatial clonal landscape in primary tumours and metastases, as well as over time.
Inclusion: Clinical diagnosis of synchronous metastatic colorectal cancer, planned cancer treatment with curative intent at the Skåne University Hospital.
Exclusion: Age below or above the age limit; Not accepting the study inclusion terms (informed consent not obtained).